I am/I care for a patient with cancer

Patient Testimonials

Herman Atzenhoefer

Herman Atzenhoefer, non-Hodgkin’s lymphoma, cancer trial participant
“Everything seems as normal as ever—but it’s not.”

“Everything seems as normal as ever—but it’s not,” says 47-year-old school bus driver Herman Atzenhoefer. Diagnosed in the fall of 2001 with aggressive, non-Hodgkin’s lymphoma, Herman was frightened. “I really didn't know much about cancer,” he says, “and nothing at all about clinical trials. But my wife and I put our trust in Dr Timothy Moore, and we’ve been counting our blessings ever since.”

Dr Moore, an oncologist at Mid-Ohio Oncology/Hematology, went over Herman’s treatment options. Herman asked him for his recommendation and, soon after, enrolled in a non-randomized Phase II trial of 4 chemotherapy drugs and the rituximab antibody (R-CHOP) combined with Neulasta® (pegfilgrastim). The recently FDA-approved Neulasta, which can rebuild the white blood cells that protect people from infection, allowed Herman’s treatment to run like clockwork while reducing the treatment from the usual 18 weeks to just 12. Within three treatment cycles, his CAT scans came back completely clear.